Introduction {#s1}
============

Psychiatric disorders represent a considerable burden for healthcare providers around the world, affecting \>20% of the global population. Despite extensive research efforts during the past decades, the aetiologies of the major psychiatric disorders schizophrenia (SZ), bipolar disorder (BD), and major depressive disorder (MDD) are largely unknown. These disorders are heterogeneous in nature, with genetic and environmental factors contributing to pathogenesis and aetiology ([@CIT0037]; [@CIT0063]; [@CIT0031]; [@CIT0014]; [@CIT0034]). Symptom profiles greatly overlap with regards to clinical psychopathology as well as putative pathophysiology ([@CIT0058]). So far, no single gene, mRNA transcript, or protein has been found that can account for the pathology of any of these disorders. However, the existence of a variety of risk genes and risk-associated protein alterations is now widely accepted. Genome-wide association studies, identifying a large number of single nucleotide polymorphisms in candidate genes and structural genetic differences such as copy number variations, as well as micro-array and proteomic analyses have greatly contributed to this knowledge ([@CIT0048]). However, at present, there is a lack of information regarding which of the genetic risk polymorphisms are associated with changes at the mRNA and protein levels.

Recent technological developments in proteomic methods have now made it possible to validate high-throughput findings with great accuracy and sensitivity ([@CIT0065]). SRM is currently the most advanced targeted mass spectrometry-based technology. In contrast to shot-gun proteomics strategies, in which the goal is to simultaneously investigate abundance changes of hundreds to thousands of proteins at the expense of sensitivity, SRM mass spectrometry platforms allow monitoring of a predetermined selection of proteins/peptides with high sensitivity, reproducibility, and quantitative accuracy ([@CIT0050]; [@CIT0049]). In addition, the SRM approach has emerged as an alternative to affinity-based assays such as enzyme-linked immune-sorbent assays with the advantage of faster and more cost-effective assay development ([@CIT0066]). Protein quantification by SRM in complex samples using predefined assay coordinates is reproducible across different laboratories and instrument platforms, facilitating reproducibility of assays in follow-up studies. Developed assays are universally applicable to test hypotheses across a variety of samples of different origins (eg, brain tissue, blood) and easily adjustable to different matrices. Therefore, SRM is ideal to investigate whether previously reported candidate risk genes for psychiatric disorders translate to changes at the protein level, providing evidence of functional effects and clinical relevance.

We designed a targeted multiple isotope labelled SRM-assay, comprising 56 proteins that have been implicated in the major psychiatric disorders and screened a total of 89 postmortem brain tissue samples of 22 SZ patients, 23 BD patients, 11 MDD patients, 11 MDD patients with psychotic features (MDD-P), and 22 healthy controls (CTs). The proteins tested have previously been associated with psychiatric pathophysiology at the gene, mRNA transcript, or protein level. Our main objective was to investigate the potential of SRM to systematically elucidate the pathophysiology of neuropsychiatric disorders and to further evaluate putative risk markers as novel molecular targets for the next generation of drugs.

Materials and methods {#s2}
=====================

Clinical Samples {#s3}
----------------

A total of 89 postmortem anterior prefrontal cortex (Broadmann Area 10) brain samples were provided by the Stanley Medical Research Institute (Bethesda, MD) ([@CIT0062]) and consisted of 22 SZ patients, 23 BD patients, 11 MDD patients without psychotic symptoms, 11 MDD-P patients with psychotic symptoms and 22 CTs. Tissue was collected postmortem from patients and controls with full informed consent obtained from a first-degree relative in compliance with the Declaration of Helsinki, and consent was obtained by questionnaires conducted over the phone and signed by 2 witnesses. The sample groups were matched for age of death, gender, and brain pH (*t* test). There were no significant differences in the brain side from which samples were obtained, secondary axis diagnosis of alcohol abuse**/**dependency, and drug abuse**/**dependency between patients and CTs (Fisher's exact test). Tissue was sectioned using a Leica Cryostat (Milton Keynes, UK) and stored at −80°C until use. All tissue samples used contained equal amounts of white and grey matter. A summary of the demographic details and statistical values is shown in [supplementary Table S1](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyu015/-/DC1). Additional information is provided in [supplementary Table S2](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyu015/-/DC1).

Sample Preparation {#s4}
------------------

Approximately 50mg of tissue per sample was used. Samples were added to fractionation buffer containing 7M urea, 2M thiourea, 4% CHAPS, 2% ASB14, and 70mM dithiothreitol at a 5:1 (vol/wt) ratio ([@CIT0019]). After sonication and vortexing for 30 minutes, protein concentrations of the lysates were determined using a Bradford assay (Bio-Rad, Hemel Hempstead, UK). Protein (approximately 100 μg) was precipitated using acetone. After dissolving the precipitate in 50mM ammonium bicarbonate, protein concentrations were determined in quadruplets. Reduction of sulfhydryl groups on proteins was performed with 5mM dithiothreitol at 60°C for 30 minutes and alkylation was carried out using 10mM iodacetamide and incubating in the dark at 37°C for 30 minutes. Proteins were digested using trypsin at a 1:50 (wt/wt) ratio for 17 hours at 37°C, and reactions were stopped by the addition of 8.8M HCl in a 1:60 (vol/vol) ratio. Sample aliquots were stored at −80°C until analysis.

Label-Based Selected Reaction Monitoring Mass Spectrometry {#s5}
----------------------------------------------------------

Abundance alterations of a panel of 56 candidate proteins implicated in the pathology of the major psychiatric disorders or associated with drug treatments were measured using targeted SRM mass spectrometry on a Xevo TQ-S mass spectrometer (Waters Corporation) coupled online through a New Objective nanoESI emitter (7cm long, 10-mm tip; New Objective) to a nanoAcquity UPLC system (Waters Corporation). The system was comprised of a C18 trapping column (180 μmx20mm, 5-μm particle size) and a C18 BEH nano-column (75 μmx200mm, 1.7-mm particle size). The separation buffers were (A) 0.1% formic acid and (B) 0.1% formic acid in acetonitrile. For separation of peptides, the following 48-minute gradient was applied: 97/3% (A/B) to 60/40% in 30 minutes; 60/40% to 15/85% in 2 minutes; 5 minutes at 15/85%; and returning to the initial condition in 1 minute. The flow rate was 0.3 µL/min and the column temperature was 35°C.

SRM assays were developed following a high-throughput strategy ([@CIT0050]) ([Figure 1a](#F1){ref-type="fig"}). We initially started with more than 200 selected proteins. Up to 12 unique peptides ranging from 6 to 20 amino acids in length containing tryptic ends and no missed cleavages were chosen for each of the selected proteins. All peptides containing amino acids prone to undergo modifications (eg, Met, Trp, Asn, and Gln), potential ragged ends, lysine/arginine followed by proline, or bearing NXT/NXS glycosylation motifs were avoided and selected only when no other options were available ([@CIT0036]). Peptides were checked by Protein BLAST (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) searches to ensure uniqueness. For method refinement, up to 12 transitions per peptide were tested in SRM mode. Transitions were calculated using Skyline version 1.2.0.3425 ([@CIT0040]) and corresponded to singly charged y-ions from doubly or triply charged precursors in the range of 350 to 1250Da. Transitions were selected based on software internal predictions, discovery proteomics data, and spectral data available through the Human NIST spectral libraries ([@CIT0021]). Method refinement was performed on quality control samples. For the final SRM assay, the 2 to 3 peptides with the maximal intensities and highest spectral library similarity (dotp) were selected. We also analyzed heavy-label spiked quality control samples ([Figure 1b](#F1){ref-type="fig"}) in scheduled SRM mode to confirm identity via coelution, extracted the optimal fragment ions for SRM analysis, obtained accurate peptide retention times, and optimized collision energy and cone voltage for the quantification run applying skyline software (MacCoss Lab Software; Seattle, WA) ([@CIT0040]). Heavy labelled forms of the selected peptides (spiketides L) were chemically synthesized via SPOT synthesis (JPT Peptide Technologies GmBH, Berlin, Germany). The final transitions, collision energy, and retention time windows used for each peptide can be found in the supplementary information ([supplementary Table S3](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyu015/-/DC1)).

![a, Schematic overview of the study design. b, left, Chromatographic SRM profile of the sample's endogenic tryptic peptide AIFTGYYGK and of the spiked heavy labelled reference peptide. Right, Chromatographic SRM profile of the transitions of the light peptide.](ijnppy_pyu015_f0001){#F1}

Quantitative SRM measurements comparing patients and controls were performed in scheduled SRM acquisition mode using the optimized parameters defined during the assay refinement. For each target peptide, a heavy isotope labelled internal standard (JPT Peptide Technologies GmbH) was spiked in the peptide mixture for accurate quantification and identification. All SRM functions had a 2-minute window of the predicted retention time and scan times were 20 milliseconds. For each peptide, at least 3 transitions were monitored for the heavy and light version. Samples were run randomized and blocked ([@CIT0046]) in triplicates, and blanks and quality control peptide injections (yeast alcohol dehydrogenase; [supplementary Table S3](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyu015/-/DC1)) were performed alternating after every biological replicate. Resulting SRM data were analyzed using Skyline and explanatory data analysis (quality assessment), and model-based statistical analysis was conducted using SRMstats ([@CIT0013]). The data preprocessing consisted of a log~2~ transformation of the data to stabilise the variance. A constant normalization was performed based on reference transitions for all proteins to equalize the median peak intensities of reference transitions from all proteins across all mass spectrometry runs and adjusted the bias to both reference and endogenous signals. Protein level quantification and testing for differential abundance among patient and control groups were carried out using the linear mixed-effects model implemented in SRMstats. The linear mixed model function supported by SRMstats employs a "restricted" or "expanded" scope of conclusions ([@CIT0013]; [@CIT0060]). In the restricted scope model, the individual samples being modelled are the population of interest, whereas in the expanded scope model, the samples being modelled are treated as a random sample from the population of interest. Consequently, the expanded scope model allowed us to draw conclusions about the population from which the samples were drawn, and the restricted scope allowed conclusions within the data itself. Initially, we assumed the restricted scope, taking into account the measurement error of transitions across runs (technical variation), to quantify protein abundance changes in our sample cohorts. Subsequently, we continued with the expanded scope, accounting for technical variation and considering the individual biological replicates (biological variation) of our sample cohorts as random selection of their respective populations of origin to test which protein changes could be considered as representative of their underlying populations. The *P*-values were adjusted to control the false discovery rate at a cut-off of 0.05 according to Benjamini and Hochberg ([@CIT0013]).

Results {#s6}
=======

Applying label-based SRM mass spectrometry, we measured differential protein abundance levels of 56 predefined proteins ([Table 1](#T1){ref-type="table"}) in postmortem brain samples from 22 SZ, 23 BD, 11 MDD, and 11 MDD-P patients compared with 22 CTs. Additionally, MDD-P was compared directly with MDD to identify proteins associated with affective psychosis in MDD. We detected common and unique alterations in individual protein levels across the disorders using a statistical modelling framework for protein significance analysis based on the SRM spectral data. The model required the scope of conclusion validity to be specified as either "restricted" or "expanded" corresponding to drawing conclusions about the data itself or about the population from which the individual samples were drawn.

###### 

Overview of the Multiplex SRM Assay

  Protein Name                                         UP-ID   Function Summary                                                                                                                                                                      CL              G   T   P   Link to                                         
  ---------------------------------------------------- ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- --- --- --- --------------------------- ------------------- -------------------
  **22q11.2 Deletion Syndrome**                                                                                                                                                                                                                                                                                                  
  Catechol O-methyltransferase                         COMT    Catalyzes inactivation, of catecholamine neurotransmitters and catechol hormones                                                                                                      22q11.21        √           \[1--4\]                    \[5, 6\]            \[7\]
  Proline dehydrogenase 1, mito                        PROD    Converts proline to delta-1-pyrroline-5- carboxylate                                                                                                                                  22q11.21        √           \[1, 8, 9\]                                     
  Ran-binding protein 1                                RANG    Inhibits GTP exchange on Ran. Increases GTP hydrolysis induced by RANGAP1                                                                                                             22q11.21        √           \[1\]                                           
  Septin 5                                             SEPT5   Filament-forming cytoskeletal GTPase, may play a role in cytokinesis                                                                                                                  22q11.21        √           \[1\]                                           
  TCA transport protein, mito                          TXTP    Involved in citrate-H^+^/malate exchange                                                                                                                                              22q11.21        √           \[1\]                                           
  **Receptors**                                                                                                                                                                                                                                                                                                                  
  Glutamate receptor 1                                 GRIA1   Ionotropic glutamate receptor (AMPA1)                                                                                                                                                 5q31.1          √           \[2, 10\]                                       
  Glutamate receptor 2                                 GRIA2   Ionotropic glutamate receptor (AMPA2)                                                                                                                                                 4q32.1              √       \[10--12\]                  \[12\]              \[12\]
  Glutamate receptor 3                                 GRIA3   Ionotropic glutamate receptor (AMPA3)                                                                                                                                                 7q21.1- q21.2       √       \[10\]                                          \[12\]
  NMDA receptor 1                                      NMDZ1   NMDA receptor subtype, high calcium permeability, voltage-dependent sensitivity to Mg^2+^                                                                                             9q34.3          √   √   √   \[10, 13, 14\]              \[15\]              \[16--18\]
  **Scaffolding proteins**                                                                                                                                                                                                                                                                                                       
  Ankyrin 3                                            ANK3    Neuronal scaffolding protein in nodes of Ranvier and axon initial segments                                                                                                            10q21           √           \[19, 20\]                  \[19, 21, 22\]      \[19\]
  Disks large homolog 4 (PSD95)                        DLG4    Interacts with the NMDA receptor subunits and shaker-type potassium channels                                                                                                          17p13.1         √   √   √   \[13, 14, 23--31\]          \[13, 23\]          
  Shank3                                               SHAN3   Post-synaptic density protein, interconnects NMDA and metabotropic glutamate receptors                                                                                                22q13.3         √           \[32--34\]                  \[35, 36\]          
  **Downstream signalling**                                                                                                                                                                                                                                                                                                      
  **Calcium signalling**                                                                                                                                                                                                                                                                                                         
  Calmodulin (CaM)                                     CaM     Calmodulin mediates the control of a large number of enzymes, ion channels by Ca^2+^                                                                                                  14q32.11                √   \[37, 38\]                                      
  CamK2α                                               KCC2A   Major protein kinase in the CNS, functions in LTP and neurotransmitter release                                                                                                        5q32                √   √                               \[39, 40\]          
  CamK2β                                               KCC2B   Function autonomously after Ca^2+^/calmodulin-binding and autophosphorylation, involved in dendritic spine and synapse formation, neuronal plasticity                                 7p14.3- p14.1       √       \[41, 42\]                                      \[41\]
  CamK2γ                                               KCC2G   10q22                                                                                                                                                                                                                                                             
  Calcineurin subunit B type 1                         CANB1   Regulatory subunit of calcineurin, Ca^2+^/ calmodulin protein phosphatase                                                                                                             2p15                    √   \[43\]                                          
  IP3 receptor isoform 1                               ITPR1   Intracellular channel, mediates calcium release from the endoplasmic reticulum                                                                                                        3p26.1                                                  \[44\]              
  Neurochondrin                                        NCDN    Involved in signal transduction, increases cell surface localization of GRM5                                                                                                          1p34.3                      \[45\]                                          
  Calmodulin-dep. calcineurin A subunit beta isoform   PP2BB   Ca^2+^-dependent, calmodulin-stimulated protein phosphatase, may have a role in the calmodulin activation of calcineurin.                                                             10q22           √       √   \[46, 47\]                                      
  **Protein Kinase**                                                                                                                                                                                                                                                                                                             
  Protein kinase C α type                              KPCA    Ca^2+^-act. Ser/Thr -protein kinase, involved in cell proliferation, apoptosis, differentiation, migration                                                                            17q22- q23.2    √       √                               \[48, 49\]          \[50\]
  Protein kinase C β type                              KPCB    Ca^2+^-act. Ser/Thr-protein kinase involved in oxidative stress-induced apoptosis & insulin signaling                                                                                 16p11.2                 √                               \[48, 49\]          \[50, 51\]
  Protein kinase C γ type                              KPCG    Ca^2+^-act. Ser/Thr-protein kinase, regulates neuronal receptor functions, mediates synaptic function                                                                                 19q13.4                 √                               \[48, 49\]          
  MARCKS                                               MARCS   MARCKS is the most prominent cellular substrate for protein kinase C                                                                                                                  6q22.2                  √                               \[52--54\]          \[55\]
  **ERK-signalling**                                                                                                                                                                                                                                                                                                             
  ERK2                                                 MK01    Serine/threonine kinase, essential component of the MAPK signal transduction pathway                                                                                                  22q11.21                √   \[56--58\]                  \[59\]              
  ERK1                                                 MK03    Serine/threonine kinase, essential component of the MAPK signal transduction pathway                                                                                                  16p11.2                 √   \[56--58\]                                      
  PED                                                  PEA15   Blocks Ras-mediated inhibition of integrin activation, modulates the ERK MAP kinase cascade                                                                                           1q21.1          √           \[60--62\]                                      
  **mTOR**                                                                                                                                                                                                                                                                                                                       
  mTOR                                                 MTOR    Central regulator of cellular metabolism, growth and survival                                                                                                                         1p36.2                  √   \[63\]                                          
  40S ribosomal protein RS3A                           RS3A    Ribosomal subunit                                                                                                                                                                     8q24.3                                                                      
  40S ribosomal protein S4, X iso.                     RS4X    Ribosomal subunit                                                                                                                                                                     Xq13.1                                                                      
  **Wnt signalling**                                                                                                                                                                                                                                                                                                             
  Catenin β-1                                          CTNB1   Key downstream component of the canonical Wnt signaling pathway                                                                                                                       3p21                    √                                                   \[64\]
  Glycogen synthase kinase-3 β                         GSK3B   Active protein kinase, neg. regulator in the hormonal control of glucose homeostasis,                                                                                                 3q13.3          √       √   \[65--67\]                  \[68--72\]          \[73, 74\]
  Phosphoprotein F1-20                                 AP180   Component of the adapter complexes which link clathrin to receptors in coated vesicles                                                                                                6q14.2          √                                       \[75\]              
  **Cell-type specific proteins**                                                                                                                                                                                                                                                                                                
  **Oligodendrocytes**                                                                                                                                                                                                                                                                                                           
  CNPase                                               CN37    Involved in RNA metabolism in the myelinating cell, third most abundant protein in CNS myelin                                                                                         17q21           √   √       \[76--79\]                                      
  Myelin basic protein                                 MBP     Most abundant component of myelin membrane, plays role in myelin formation and stabilization                                                                                          18q23           √   √       \[2, 80--84\]               \[83\]              \[84\]
  Myelin proteolipid protein                           MYPR    Major myelin protein from CNS, plays role in multi-laminar myelin formation or maintenance                                                                                            Xq22                √       \[85, 86\]                                      \[87\]
  Myelin-oligodendrocyte glycoprotein                  MOG     Minor component of the myelin sheath, myelin sheath completion/maintenance, cell-cell communication                                                                                   6p22.1              √       \[88--90\]                  \[88\]              \[87\]
  **Astrocytes**                                                                                                                                                                                                                                                                                                                 
  Glial fibrillary acidic protein                      GFAP    GFAP, a class-III intermediate filament, is a cell-specific marker for astrocytes                                                                                                     17q21               √   √   \[91--94\]                                      \[95, 96\]
  **Microglia**                                                                                                                                                                                                                                                                                                                  
  Coronin-1A                                           COR1A   Crucial component of the cytoskeleton of highly motile cells                                                                                                                          16p11.2         √       √   \[94, 97--100\]                                 
  **Energy metabolism**                                                                                                                                                                                                                                                                                                          
  ATP synthase subunit b                               ATP5F   Mitochondrial membrane ATP synthase                                                                                                                                                   18q21           √   √   √   \[101\]                     \[102\]             \[103\]
  Citrate synthase, mito                               CISY    Pace-making enzyme in the first step of the tricarboxylic acid cycle (TCA)                                                                                                            12q13.2                 √   \[104\]                                         
  Complex I-75 kDa                                     NDUS1   Core subunit of the mitochondrial membrane respiratory chain, required for catalysis                                                                                                  2q33-q34            √   √   \[105--107\]                \[107, 108\]        \[107\]
  Malate dehydrogenase                                 MDHC    Catalyzes the oxidation of malate to oxalacetate, involved in TCA, gluconeogenesis                                                                                                    2p13.3          √   √   √   \[11, 78, 105, 109--112\]                       
  Phosphoglycerate kinase 1                            PGK1    Major ATP-generating enzyme in glycolysis, reversed reaction in gluconeogenesis                                                                                                       Xq13.3                  √   \[113\]                                         \[114\]
  Triosephosphate isomerase                            TPIS    Glycolytic enzyme, seems to act as a polymerase alpha cofactor protein                                                                                                                12p13                   √   \[94, 113\]                                     
  **Oxidative Stress**                                                                                                                                                                                                                                                                                                           
  Catalase                                             CATA    Protects cells from the toxic effects of hydrogen peroxide                                                                                                                            11p13           √       √   \[115, 116\]                                    \[117--120\]
  Glutathione peroxidase 1                             GPX1    Protects the hemoglobin in erythrocytes from oxidative breakdown                                                                                                                      3p21.3          √       √   \[121--123\]                                    \[124\]
  Protein DJ-1                                         PARK7   Protects cells against oxidative stress and cell death                                                                                                                                1p36.23                 √   \[104, 125\]                                    
  Peroxiredoxin-3                                      PRDX3   Redox regulation of the cell. Protects radical- sensitive enzymes from oxidative damage                                                                                               10q25-q26                                                                   
  **Neuronal structure/plasticity**                                                                                                                                                                                                                                                                                              
  Amyloid beta A4 protein                              A4      cell surface receptor, plays role in neurite growth, neuronal adhesion and axonogenesis                                                                                               21q21           √           \[126\]                     \[127\]             
  BDNF/NT-3 growth factors receptor                    NTRK2   Receptor tyrosine kinase, involved in the nervous system development via regulation of neuron survival, proliferation, migration, differentiation, synapse formation and plasticity   9q22.1          √   √   √   \[128--130\]                \[128, 131--133\]   \[128, 134--138\]
  Neural cell adhesion molecule 1                      NCAM1   Cell adhesion molecule involved in neuron- neuron adhesion, neurite fasciculation & outgrowth                                                                                         11q23.1         √       √   \[2, 139\]                                      \[140\]
  Neuromodulin                                         NEUM    Major component of the motile "growth cones", role in axonal and dendritic filopodia induction                                                                                        3q13.31                 √   \[141, 142\]                \[142\]             
  Neurofilament light polypeptide                      NFL     Maintenance of neuronal caliber                                                                                                                                                       8p21                √   √   \[28\]                      \[143\]             
  **Transcription Factors**                                                                                                                                                                                                                                                                                                      
  Nuclear factor NF- kappa-B p105                      NFKB1   Pleiotropic transcription factor, endpoint of a series of signal transduction events                                                                                                  4q24                √       \[144\]                     \[145, 146\]        
  Transcriptional activator protein Purα               PURA    Transcription activator, plays a role in the initiation of DNA replication and in recombination                                                                                       5q31                √                                   \[147\]             

Abbreviations: CL, chromosome location; G, implicated at genetic level; P, implicated at protein level; T, implicated at transcript level; UP-ID, UniProt identification code.

Assays were selected based on literature findings. For references, see [supplementary Table S4](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyu015/-/DC1).

Statistical analysis using the restricted model resulted in the identification of 12 differentially expressed proteins in the SZ/CT, 27 in BD/CT, 11 in MDD/CT, 6 in MDD-P/CT, and 15 in the MDD-P/MDD group comparisons ([Table 2](#T2){ref-type="table"}).

###### 

Significantly Changed Proteins Identified By Label-Based LC-SRM in the SZ/CT, BD/CT, MDD/CT, MDD-P/CT, and MDD-P/MDD Comparisons

  Protein                                   SZ/CT                                BD/CT             MDD/CT            MDD-P/CT          MDD-P/MDD                                                                                                                                                                                                                                                       
  ----------------------------------------- ------------------------------------ ----------------- ----------------- ----------------- ------------------------------------------------------------------------------- ------------------------------------------------------------ -------------------------------- ----------------- ----------------- ----------------- ----------------- --------- -------
  **22q11.2 Deletion Syndrome**                                                                                                                                                                                                                                                                                                                                                                        
  Catechol O-methyltransferase              not significant                      1.25              0.0038            0.0102            not significant                                                                 not significant                                              not significant                                                                                                    
  Ran-binding protein 1                     not significant                      not significant   1.16              0.009             0.048                                                                           not significant                                              not significant                                                                                                    
  Septin 5                                  0.66                                 7.0E-06           7E-05             not significant   not significant                                                                 not significant                                              not significant                                                                                                    
  not significant in any comparison:                                                                                                                                                                                   TCA transport protein, mito; Proline dehydrogenase 1, mito                                                                                                                      
  **Receptors**                                                                                                                                                                                                                                                                                                                                                                                        
  Glutamate receptor 2                      not significant                      1.16              0.0039            0.0102            not significant                                                                 not significant                                              not significant                                                                                                    
  NMDA receptor 1                           not significant                      1.27              0.019             0.0418            not significant                                                                 not significant                                              not significant                                                                                                    
  not significant in any comparison:                                                                                                                                                                                   Glutamate receptor 1, Glutamate receptor 3                                                                                                                                      
  **Scaffolding proteins**                                                                                                                                                                                                                                                                                                                                                                             
  Ankyrin-3                                 not significant                      not significant   1.17              0.003             0.019                                                                           0.80                                                         4.9E-05                          0.0006            0.68              1.1E-09           6E-08                       
  Disks large homolog 4 (PSD95)             0.88                                 1.0E-03           0.006             1.13              0.002                                                                           0.006                                                        not significant                  not significant   not significant                                                 
  not significant in any comparison:        Shank 3                                                                                                                                                                                                                                                                                                                                                    
  **Downstream signalling**                                                                                                                                                                                                                                                                                                                                                                            
  **Calcium signalling**                                                                                                                                                                                                                                                                                                                                                                               
  CamK2α                                    not significant                      1.12              0.0002            0.0007            not significant                                                                 not significant                                              0.88                             0.0035            0.026                                                           
  CamK2β                                    not significant                      not significant   1.15              8E-04             0.008                                                                           not significant                                              0.87                             0.00515           0.031                                                           
  CamK2γ                                    not significant                      1.22              2E-07             1E-06             1.21                                                                            6E-05                                                        0.001                            not significant   0.87              0.01239           0.05                        
  PP2BB                                     not significant                      not significant   not significant   not significant   0.83                                                                            0.00447                                                      0.03                                                                                                               
  Calcineurin subunit B type 1              not significant                      1.19              0.0052            0.012             not significant                                                                 not significant                                              not significant                                                                                                    
  Neurochondrin                             not significant                      1.19              0.0051            0.012             not significant                                                                 not significant                                              not significant                                                                                                    
  not significant in any comparison:        Calmodulin, IP3 receptor isoform 1                                                                                                                                                                                                                                                                                                                         
  **Protein Kinase**                                                                                                                                                                                                                                                                                                                                                                                   
  Protein kinase C α type                   not significant                      1.17              0.0015            0.0048            not significant                                                                 not significant                                              not significant                                                                                                    
  Protein kinase C γ type                   not significant                      not significant   not significant   not significant   0.85                                                                            0.01158                                                      0.05                                                                                                               
  MARCKS                                    not significant                      1.10              0.0086            0.02              not significant                                                                 not significant                                              not significant                                                                                                    
  not significant in any comparison:        Protein kinase C, β type                                                                                                                                                                                                                                                                                                                                   
  **ERK-signalling**                                                                                                                                                                                                                                                                                                                                                                                   
  ERK1                                      not significant                      1.11              5E-05             0.0002            1.10                                                                            0.002                                                        0.015                            not significant   0.88              0.00046           0.005                       
  not significant in any comparison:        ERK2, PED                                                                                                                                                                                                                                                                                                                                                  
  **mTOR**                                                                                                                                                                                                                                                                                                                                                                                             
  40S ribosomal protein S4, X isoform       not significant                      1.16              0.0004            0.0014            not significant                                                                 not significant                                              0.85                             0.00853           0.043                                                           
  not significant in any comparison:        mTOR, 40S ribosomal protein RS3A                                                                                                                                                                                                                                                                                                                           
  **Wnt signalling**                                                                                                                                                                                                                                                                                                                                                                                   
  Catenin β-1                               not significant                      1.21              1E-06             7E-06             not significant                                                                 not significant                                              not significant                                                                                                    
  Glycogen synthase kinase-3 β              0.90                                 7.5E-03           0.041             1.13              0.0037                                                                          0.0102                                                       not significant                  not significant   not significant                                                 
  'not significant in any comparison                                                                                                                                                                                                                                                Phosphoprotein F1-20                                                                                               
  **Cell-type specific proteins**                                                                                                                                                                                                                                                                                                                                                                      
  **Oligodendrocytes**                                                                                                                                                                                                                                                                                                                                                                                 
  CNPase                                    0.79                                 1.1E-07           2.2E-06           0.53              \<1E-16                                                                         \<1E-16                                                      not significant                  0.79              1.8E-05           0.0003            not significant             
  Myelin basic protein                      0.79                                 2.3E-06           2.7E-05           0.64              \<1E-16                                                                         \<1E-16                                                      not significant                  0.79              1.4E-04           0.0014            not significant             
  Myelin proteolipid protein                0.79                                 2.1E-11           6.2E-10           0.61              \<1E-16                                                                         \<1E-16                                                      not significant                  0.82              2.1E-06           4E-05             not significant             
  Myelin-oligodendrocyte glycoprotein       0.79                                 2.4E-12           1.5E-10           0.56              \<1E-16                                                                         \<1E-16                                                      not significant                  0.82              1.5E-06           4E-05             0.86              0.00131   0.011
  **Astrocytes**                                                                                                                                                                                                                                                                                                                                                                                       
  Glial fibrillary acidic protein           0.89                                 1.7E-04           0.001             not significant   0.83                                                                            5E-07                                                        3E-05                            0.79              8.4E-11           5E-09             not significant             
  **Microglia**                                                                                                                                                                                                                                                                                                                                                                                        
  Coronin-1A                                not significant                      not significant   0.77              4E-04             0.005                                                                           not significant                                              not significant                                                                                                    
  **Energy metabolism**                                                                                                                                                                                                                                                                                                                                                                                
  Citrate synthase, mito                    not significant                      1.17              0.0001            0.0004            not significant                                                                 not significant                                              not significant                                                                                                    
  Complex I-75 kDa                          not significant                      1.25              0.0002            0.0006            not significant                                                                 not significant                                              not significant                                                                                                    
  Malate dehydrogenase, mito                0.93                                 8.5E-03           0.042             1.19              1E-10                                                                           1E-09                                                        1.11                             0.002             0.015             not significant   0.91              0.01183   0.05
  not significant in any comparison                                                                                                    ATP synthase subunit b, Phosphoglycerate kinase 1, Triose phosphate isomerase                                                                                                                                                                                   
  **Oxidative Stress**                                                                                                                                                                                                                                                                                                                                                                                 
  Peroxiredoxin-3                           not significant                      1.19              1E-06             7E-06             not significant                                                                 not significant                                              not significant                                                                                                    
  not significant in any comparison                                                                                                                                                                                    Glutathione peroxidase 1, Protein DJ-1, Catalase                                                                                                                                
  **Neuronal structure/plasticity**                                                                                                                                                                                                                                                                                                                                                                    
  Neuromodulin                              0.89                                 3.6E-04           0.003             not significant   not significant                                                                 not significant                                              1.17                             0.0007            0.007                                                           
  Neurofilament light polypeptide           0.91                                 6.8E-04           0.005             0.84              5E-11                                                                           6E-10                                                        1.10                             0.002             0.015             not significant   0.86              6.3E-05   0.002
  not significant in any comparison:                                                                                                   APP A4; Neural cell adhesion molecule 1; BDNF/NT-3 growth factors receptor                                                                                                                                                                                      
  **Transcription factors**                                                                                                                                                                                                                                                                                                                                                                            
  Transcriptional activator protein Pur-α   not significant                      1.13              2E-05             1E-04             1.18                                                                            1E-05                                                        2E-04                            not significant   0.85              0.00016           0.002                       
  not significant in any comparison:                                                                                                                                                                                                                                                Nuclear factor NF-kappa-B p105                                                                                     

Abbreviations: BD, bipolar disorder; CT, controls; MDD, major depressive disorder; SZ, schizophrenia.*P*-values were determined using SRMstats (fixed-subject effects) and corrected to control for multiple hypothesis testing after Benjamini-Hochberg (Chang et al., 2011). Significant findings using the mixed subject effect model of the SRMstats framework are indicated by grey shading. For reasons of clarity, only ratios and significance levels of significantly changing proteins are shown. For full information, see [supplementary Table S5](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyu015/-/DC1).

Most alterations in protein abundance levels were found in the BD/CT comparison in which the majority of proteins were increased, with the exception of oligodendrocyte-specific proteins (CN37, MBP, MOG, MYPR) and neurofilament light polypeptide, which were decreased. A less pronounced decrease in oligodendrocyte-specific proteins was found in the SZ/CT and MDD-P/CT comparisons. In MDD/CT, lower levels of the astrocyte marker glial fibrillary acidic protein and the microglia marker coronin 1a were identified. In the BD/CT comparison, the Wnt signalling pathway appeared to be upregulated. The MDD/CT comparison showed increases in calmodulin-dependent protein kinase 2 subunits β and γ as well as ERK signalling. All proteins found to be significantly different in MDD-P/MDD were decreased similar to the finding in the SZ/CT comparison, although this involved different proteins. In the MDD-P/MDD comparison, all 3 calmodulin-dependent protein kinase 2 subunits (CAMK2α, CAMK2β, CAMK2y) were decreased. To test for potential medication effects, we correlated the SRM intensity estimates and fluphenazine milligram equivalents and found no significant effect on any measured protein (Spearman correlation *P*\>.1). However, effects of other psychotropic medication such as antidepressants and mood-stabilizing agents cannot be ruled out. To exclude further confounding effects, we correlated the SRM intensity estimates and additional demographic characteristics (brain pH, postmortem interval, age of death, age of disease onset, disease duration). We were unable to find any correlation (Spearman correlation *P*\>.1). For further information, see [supplementary Table S6](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyu015/-/DC1).

Since these proteomic findings resulted from the analysis of our sample cohort, we subsequently applied an expanded model to determine the likelihood of finding similar results in a wider population. These results supported the decrease in oligodendrocytic proteins (MBP, MOG, MYP, CN37) in BD/CT and the decrease of Septin 5 (SEPT5) in SZ/CT and Ankyrin 3 (ANK3) in MDD-P/MDD ([Figure 2](#F2){ref-type="fig"}).

![Box plots of the normalized SRM estimates illustrating the proteins detected as significantly changed in the expanded model. Ratios represent disease/CT or MDD-P/MDD, respectively.](ijnppy_pyu015_f0002){#F2}

Discussion {#s7}
==========

This study represents the first and largest label-based quantitative targeted proteomics investigation in human brain tissue to date, evaluating expression changes of high-risk genes and risk-associated proteins in 4 different psychiatric disorders.

Applying linear mixed effect models, we were able to detect a range of significantly altered proteins that have been implicated at the genetic, transcriptomic, and proteomic levels in psychiatric research. We provide evidence for microglial dysfunction in MDD ([@CIT0022]; [@CIT0035]) compared with controls as shown by a decrease in coronin 1A levels. The astrocyte marker glial fibrillary acidic protein was decreased in SZ and MDD, indicating a potential disturbance of neuronal maintenance and glutamate clearance, and all CamK2 isoforms were changed in the MDD-P/MDD comparison. In addition, we identified a decrease of proteins associated with energy metabolism in SZ and an increase in BD and MDD, in line with previous findings ([@CIT0051]; [@CIT0041]). It is also of note that we were able to validate the widely reported expression changes of malate dehydrogenase in psychiatric disorders.

One of the most striking results in this study was the systematic decrease of all investigated oligodendrocyte-specific proteins in SZ, BD, and MDD-P. Myelin-related abnormalities have previously been observed in postmortem brain and imaging studies of SZ and BD ([@CIT0015]; [@CIT0018]; [@CIT0010]; [@CIT0042]; [@CIT0002]; [@CIT0006]). In accordance with previous findings of mRNA changes ([@CIT0061]), this is the first study to show a more prominent decrease in oligodendrocyte-specific proteins in BD compared with SZ. Myelination in the prefrontal cortex occurs predominantly in adolescence and early adulthood ([@CIT0008]), consistent with the typical age of onset of SZ and BD. Interestingly, myelination deficits in SZ, BD, and MDD-P corresponded with changes in the expression of the GSK3β and Wnt signalling regulatory protein catenin β in SZ and BD. GSK3β is a negative regulator of oligodendrocyte differentiation and myelination and has been implicated in BD and SZ. GSK3β inhibitors such as lithium are widely prescribed as mood stabilizers in the treatment of BD and are known to increase oligodendrocyte differentiation and promote myelination ([@CIT0004]). Furthermore, the NMDA receptor subunit NR1, which we found to be upregulated in BD, is a functional regulator of oligodendrocyte precursor cell differentiation and remyelination ([@CIT0038]). Consequently, the development and re-profiling of drugs that promote remyelination may represent novel pharmacological targets for psychiatric disorders, especially BD. The compound XAV939 has been shown to enhance oligodendrocyte differentiation and remyelination by stabilizing Axin2, an intracellular target of Wnt transcriptional activation ([@CIT0020]). In addition, synthetic and natural cannabinoids have been shown to protect oligodendrocytes and oligodendrocyte progenitor cells and to enhance myelination by promoting oligodendrocyte maturation in vivo and vitro ([@CIT0044]; [@CIT0025]; [@CIT0059]; [@CIT0043]). They are currently being tested for efficacy in multiple sclerosis clinical trials ([@CIT0070]; [@CIT0064]) and could be evaluated for the treatment of SZ and BD ([@CIT0016]).

We also found that ANK3 protein levels were reduced in affective psychosis, supporting the finding on a wider population scale applying the expanded model. The ANK3 protein is involved in neuronal scaffolding and the formation and maintenance of the axon initial segment of neurons and nodes of Ranvier ([@CIT0009]). Recently, a meta-analysis of the major psychiatric disorders suggested that the *ANK3* locus represents a shared risk gene for a number of psychiatric disorders ([@CIT0058]). ANK3 polymorphisms have been associated with cognitive and behavioral dysfunction, including increased risk taking ([@CIT0055]) and startle response ([@CIT0053]), decreased sustained attention ([@CIT0055]; [@CIT0026]), impaired set-shifting ([@CIT0039]), and increased novelty seeking and anhedonia ([@CIT0003]; [@CIT0053]). Interestingly, common ANK3 risk alleles in BD and SZ have been linked to both increased and decreased mRNA expression, dependent on the brain region under investigation ([@CIT0054]; [@CIT0056]). The identification of ANK3 in our study further supports the pathological relevance of this gene/protein in multiple psychiatric disorders and especially in affective psychosis. Neuroimaging studies have associated ANK3 risk alleles with decreased white matter integrity in line with our findings of decreased oligodendrocyte markers in affective psychosis. BD is clinically characterized by a higher frequency of psychotic symptoms compared with MDD ([@CIT0045]), whereas other studies have suggested an affective-psychotic continuum between MDD, BD, and schizoaffective disorder ([@CIT0023]).

Another interesting finding of our study was a 40% decrease in the levels of SEPT5 in SZ patients only, which was supported by the population-based model. SEPT5 belongs to a family of evolutionarily well-conserved polymerizing GTP-binding proteins that contribute to the lateral compartmentalization of membranes, cortical rigidity, and regulation of membrane trafficking ([@CIT0033]). Notably, SEPT5 has been colocalized with presynaptic vesicles ([@CIT0007]; [@CIT0032]), plays a role in membrane fusion during neuronal exocytosis ([@CIT0001]), and is critical for dendritic spine morphology ([@CIT0067]). Decreased levels of SEPT5 in SZ prefrontal cortex may be associated with abnormal neurotransmitter secretion, for example glutamatergic hypofunction ([@CIT0047]) and abnormal dendritic spine morphology in the prefrontal cortex of SZ patients ([@CIT0024]; [@CIT0011]). In terms of pathophysiology, *SEPT5* is a strong new candidate gene, as it is located on chromosome 22q11.2. In this chromosomal region, heterozygous deletions comprising either 3 or 1.5 Mbp (affecting 90% or 10% of patients, respectively) cause the 22q11.2 Deletion Syndrome. The phenotype of this syndrome is variable, but characteristic signs and symptoms include learning disabilities, dysfunctional social behavior and SZ, and autism spectrum disorders. Approximately one-third of adults with 22q11.2 Deletion Syndrome develop SZ-like symptoms ([@CIT0030]; [@CIT0028]; [@CIT0027]). Interestingly, 3 major SZ susceptibility genes (catechol O-methyltransferase, probable palmitoyltransferase, and mitochondrial proline dehydrogenase 1) are located in this chromosome region. However, it is still unclear which of the deleted genes or gene interactions contribute to the risk of developing the neuropsychiatric phenotype. The current study provides evidence that *SEPT5* may represent a novel risk gene for psychiatric disorders. As the SEPT5 protein is phosphorylated by cyclin-dependent kinase 5 to modulate exocytotic secretion ([@CIT0001]), drugs targeting this kinase might represent a novel treatment approach for SZ. A *SEPT5* knockout mouse ([@CIT0017]) and a patient case report of SEPT5 deficiency ([@CIT0005]) demonstrated reduced dense granule secretion in platelets, suggesting that there may be a potential link of this protein to the periphery. Three independent studies showed reduced platelet-dense granule secretion in first-episode psychosis individuals and SZ patients ([@CIT0068], [@CIT0069]; [@CIT0052]).

In summary, we have employed a hypothesis-driven, label-based SRM approach and generated the largest quantitative targeted proteomics data set to date in human postmortem brain tissue and specifically for neuropsychiatric disorders. We were able to confirm changes in protein levels of previously reported risk factors for psychiatric disorders and identified novel putative risk factors for SZ and affective psychosis (SEPT5 and ANK3). Testing a wide range of previously described molecular risk factors for neuropsychiatric disorders, this is the first study to follow up risk genes and validate findings at the protein and functional level. We were able to demonstrate that myelination abnormalities are prominent in SZ, BD, and affective psychosis, as implicated by overlapping changes in several oligodendrocyte protein markers. We have also shown that GSK3b and Wnt signalling is altered in BD and SZ, and CamK2 abnormalities are prominently changed in BD and affective psychosis postmortem brain, indicating potential novel drug targets.

Our study highlights the potential of SRM to analyze protein abundance levels of candidate markers of neuropsychiatric spectrum disorders in a highly quantitative manner, thus providing a high-throughput multiplex method to validate and quantify potential disease markers and drug targets. So far, targeted proteomics has been employed in only a small number of clinical studies ranging from oncology ([@CIT0012]) to neurology ([@CIT0029]) and covering a range of biofluids ([@CIT0057]). Because of increased throughput and sensitivity compared with shotgun approaches, SRM will enable the evaluation and validation of protein biomarkers during the hypothesis-generating phase of drug discovery. Universally applicable SRM assays for disease-associated proteins will also accelerate preclinical biomarker discovery and validation studies, facilitating the transfer of pathophysiological hypotheses towards clinical application and translation.
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